Article Text

Download PDFPDF
Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis
  1. Carl Turesson1,
  2. Linda Mathsson2,
  3. Lennart T H Jacobsson1,3,
  4. Gunnar Sturfelt4,
  5. Johan Rönnelid2
  1. 1Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
  2. 2Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
  3. 3Department of Rheumatology and Inflammation Research, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  4. 4Section of Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
  1. Correspondence to
    Dr Carl Turesson, Department of Rheumatology, Skåne University Hospital, Inga-Marie Nilssons gata 32, Malmö S-205 02, Sweden; Carl.Turesson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Circulating antibodies against citrullinated peptides are highly specific for rheumatoid arthritis (RA), and associated with RA disease progression.1 ,2 We have previously reported that antibodies to cyclic citrullinated peptides (anti-CCP) are associated with severe extra-articular RA (ExRA) manifestations, although rheumatoid factor (RF) levels seemed to be more important in active ExRA than anti-CCP levels.3

Another RA-related antibody, the anti-Sa antibody, which has been associated with severe joint damage in RA,4 reacts with citrullinated vimentin.5 Most studies have shown that antibodies to modified citrullinated vimentin (anti-MCV) have a higher sensitivity but a lower specificity for RA than anti-CCP, although there are conflicting results.6 To our knowledge, no studies have previously reported on the relation between anti-MCV and severe ExRA.

We enrolled 35 …

View Full Text


  • Contributors Study concept and design: CT, LTHJ, GS, JR; acquisition of data: CT, LM, LTHJ, JR; analysis and interpretation of data: CT, LM, LTHJ, GS, JR; drafting of manuscript: CT, JR. All authors contributed to critical revision of the manuscript for important intellectual content.

  • Funding The Swedish Research Council (2010–2891), Lund University, the Åke Viberg foundation and the Swedish Rheumatism Association.

  • Competing interests None.

  • Ethics approval Regional Ethical Review Board in Lund, Sweden.

  • Provenance and peer review Not commissioned; externally peer reviewed.